Thus selective inhibition of tumour-associated isoforms hCA IX and XII (over the off-target hCA I and II) is a great promise for the use of CA inhibitors in the cancer therapy/diagnosis4,.5 This evidence concerns the gene CYP24A1 and neoplasm.